This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Craniofacial dysostosis크루존병 (두개안면골이골증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q75.1 | Special Copayment Reduction: V151 | Re-certification cycle: 5 years
B. SynonymsCraniofacial dysostosis
C. Adult onsetLikelihood of first onset in adulthood low (possible in some) — Crouzon disease is mostly diagnosed in the neonatal period or infancy, but mild phenotypes may remain undiagnosed into childhood or adolescence. Cases first diagnosed in adulthood due to increased intracranial pressure or decreased vision are rarely reported.
1. History1912: first described by the French neurologist Crouzon. 1994: FGFR2 variants identified as the cause. Corrective surgery advanced with Tessier's innovations in craniofacial surgery.
2. CausesFGFR2 gain-of-function variants. 85% are substitutions of cysteine residues in the IgIII domain. Autosomal dominant; 50% are de novo mutations. Associated with advanced paternal age.
3. GeneticsFGFR2 exon IIIa/IIIc variants (C342R, C342W, Y340C, W290C, etc.). FGFR3 p.A391E → Crouzon disease with acanthosis nigricans. Phenotypic diversity (variable expressivity). Penetrance nearly complete.
4. General epidemiologyAbout 1 in 25,000–65,000 births. A relatively common syndromic form among craniosynostoses. No sex difference. About 4.5% of all craniosynostosis.
5. PathophysiologyConstitutive activation of FGFR2 → premature ossification of sutural mesenchymal cells. Midface skeletal growth failure (midface hypoplasia). Insufficient cranial volume relative to brain growth → increased intracranial pressure → optic nerve damage.
6. SymptomsCranial deformity (premature fusion of multiple sutures), midface hypoplasia, exophthalmos, symptoms of increased intracranial pressure (headache, vomiting), obstructive sleep apnea, conductive hearing loss, nasopharyngeal stenosis.
7. SignsExophthalmos (Hertel ≥18mm), papilledema, mandibular prognathism, maxillary retrusion, intracranial digital impressions. Possible accompanying Chiari I malformation. Acanthosis nigricans (FGFR3 variant type).
8. ScreeningPrenatal ultrasound (cranial and orbital abnormalities). Assessment of neonatal head shape. Prenatal genetic testing in families with a family history.
9. DiagnosisCranial CT with 3D reconstruction, FGFR2/FGFR3 genetic testing, brain MRI, ophthalmology (papilledema, vision), polysomnography.
10. TreatmentCranioplasty (FOA, CVR), midface advancement (LeFort III, monobloc, distraction osteogenesis), airway management (CPAP, tracheostomy), ophthalmologic treatment, hearing rehabilitation.
11. PrognosisIntelligence mostly normal (with adequate management of intracranial pressure). Preservation of vision is key. Repeated surgery required. Psychosocial support important.
12. PreventionGenetic counseling and prenatal diagnosis. Early detection and treatment of increased intracranial pressure and decreased vision. Management of the airway and sleep apnea.
13. ReferencesReardon W et al. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet. 1994 and 9 other references

1. History

Crouzon disease (craniofacial dysostosis) was first described in 1912 when the French neurologist Octave Crouzon (1874–1938) reported a family with craniofacial malformations occurring across two generations (mother and son). Crouzon described the combination of multisuture craniosynostosis, midface hypoplasia, exophthalmos, and mandibular prognathism as characteristic and named it 'hereditary craniofacial dysostosis (dysostose cranio-faciale héréditaire)'. The pattern of occurrence within the family suggested autosomal dominant inheritance, but the cause remained unknown for decades.

In the mid-20th century, groundbreaking advances were made in the classification and treatment of craniofacial malformations. In 1967, Paul Tessier established craniofacial surgery and developed fronto-orbital advancement, LeFort III osteotomy, monobloc osteotomy and other procedures, making fundamental correction of the cranial and midface deformities of Crouzon disease possible. Tessier's work dramatically improved the functional and aesthetic outcomes of patients with craniofacial malformations, including Crouzon disease.

The molecular genetic cause was identified in 1994, when a British group (Reardon et al.) and a German group (Jabs et al.) independently showed that gain-of-function variants in the FGFR2 (Fibroblast Growth Factor Receptor 2) gene cause Crouzon disease. This was a historic discovery, the first identification of an FGFR gene abnormality in craniosynostosis-related syndromes. Related discoveries followed in succession, including FGFR1 (Pfeiffer syndrome) and FGFR3 (Muenke syndrome, Crouzon disease with acanthosis nigricans), establishing the FGF signaling pathway as a key regulator of cranial suture development.

Since the 2000s, the FGFR3 p.A391E variant has been reported to cause a distinct phenotype of Crouzon disease accompanied by acanthosis nigricans. Advanced surgical techniques, such as expanded clinical use of distraction osteogenesis, virtual surgical planning and custom 3D-printed implants, have been introduced into the treatment of Crouzon disease, improving surgical precision and outcomes. In Korea as well, a multidisciplinary treatment system for Crouzon disease has been established through collaboration between pediatric neurosurgery and craniofacial surgery.

2. Causes

The cause of Crouzon disease is gain-of-function variants in the FGFR2 (Fibroblast Growth Factor Receptor 2) gene; these variants constitutively activate the FGF receptor independently of ligand, inducing premature ossification of cranial suture mesenchymal cells. Of the four FGF receptors (FGFR1–4), FGFR2 plays the most important role in cranial development, and variants are concentrated in the ligand-binding domain between immunoglobulin-like domains IIIa and IIIc.

Molecular characteristics of pathogenic variants: about 85% of FGFR2 variants in Crouzon disease are substitutions of cysteine residues located in immunoglobulin-like domain III (IgIII), which promote receptor dimerization even without ligand through formation of abnormal disulfide bonds. Representative variants: p.C342R (most common, exon IIIa), p.C342W, p.Y340C, p.W290C (IgIII). Some Crouzon disease variants are found at the same positions as in Pfeiffer syndrome (types 2 and 3), suggesting that the genotype–phenotype correlation is not simple.

Mode of inheritance: autosomal dominant (AD) inheritance; 50% of children born to an affected parent are affected. About 50% of all patients with Crouzon disease result from de novo mutations, and the remaining 50% inherit the condition from an affected parent. Advanced paternal age is known to be a major risk factor for de novo mutations. This is explained by the 'selfish sperm selection' phenomenon, in which cells carrying certain FGF receptor variants have a selective proliferative advantage during spermatogenesis.

FGFR3 variant and Crouzon disease with acanthosis nigricans: the FGFR3 p.A391E variant causes a unique phenotype with generalized acanthosis nigricans in addition to craniosynostosis (a Crouzon disease-like phenotype). This variant is located in the transmembrane domain of FGFR3 and promotes receptor dimerization, also activating FGFR3 signaling in skin keratinocytes. Acanthosis nigricans presents together with the Crouzon disease phenotype as skin hyperpigmentation and hyperkeratosis of the neck, axillae and groin.

3. Genetics

Crouzon disease is an autosomal dominant disorder caused by variants in the FGFR2 gene, located at 10q26. The FGFR2 gene consists of 20 exons, and most (over 85%) pathogenic variants associated with Crouzon disease are concentrated in exon IIIa (exon 7) and exon IIIc (exon 10). These regions are the coding sequences of immunoglobulin-like domains IIIa and IIIc, which determine FGF ligand-binding specificity.

Major pathogenic variants: the variant most frequently identified in Crouzon disease is p.C342R (c.1024T>C), accounting for about 25% of the total. Next most common are cysteine residue substitutions such as p.C342W, p.C342S, p.Y340C, p.W290C and p.C278F. These cysteine residues are involved in disulfide bond formation within the IgIII domain; when substituted, abnormal disulfide bonds form and receptor dimerization persists independently of ligand. Variants in exon B (the region corresponding to exon IIIb) have been reported as rare variants, but their clinical significance is rare.

Phenotypic variability: phenotypic severity can differ greatly even among family members carrying the same gene variant. In patients with the same p.C342R variant, raised intracranial pressure, the degree of proptosis and the severity of midface retrusion appear differently. This phenotypic variability is understood to result from modifier genes, environmental factors and epigenetic differences, but the exact mechanism has not been fully elucidated. Penetrance is nearly complete, so most carriers of pathogenic FGFR2 variants express craniofacial abnormalities.

Allelism of FGFR2 variants with other syndromes: Crouzon disease, Apert syndrome, Pfeiffer syndrome types 2 and 3, Jackson-Weiss syndrome and Beare-Stevenson syndrome are all caused by different variants in the FGFR2 gene and are allelic disorders. Some variants have been reported in two syndromes (e.g., p.C342R can occur in both Crouzon and Pfeiffer), so genotype–phenotype prediction is not complete. For this reason, combining clinical diagnosis with genetic testing is essential. Genetic testing starts with FGFR2 testing alone and, if negative, is expanded to a panel including FGFR1 and FGFR3 or to WES.

4. General epidemiology

Crouzon disease is one of the most common single-gene causes of syndromic craniosynostosis, reported to occur in about 1 in 25,000–65,000 births (figures vary by source). It accounts for about 4.5% of syndromic forms among all patients with craniosynostosis and, among syndromic craniosynostoses, is the most common together with Muenke syndrome.

Sex differences: there is no clear sex predilection in Crouzon disease; males and females are affected with equal frequency. This is consistent with autosomal dominant inheritance. Geographic and ethnic distribution: evidence for differences in incidence among specific ethnic groups or regions is lacking, but in populations with a high rate of consanguineous marriage, homozygous carriers may arise, in which case a more severe phenotype may appear. Because advanced paternal age increases the risk of de novo mutations, sporadic occurrence may increase somewhat in populations with older paternal age.

De novo versus inherited cases: about 50% of all patients with Crouzon disease are sporadic cases due to de novo mutations, and the remaining 50% are inherited from an affected parent. This proportion contrasts with Apert syndrome (about 97% de novo mutations). In family history investigations of patients with Crouzon disease, family members with mild phenotypes often remain undiagnosed, so systematic evaluation of family members is important for improving the accuracy of epidemiological data.

Epidemiology in Korea: in Korea, Crouzon disease is a rare disease designated for Special Copayment Reduction (V151) under National Health Insurance, and the number of newly registered patients per year is estimated at several dozen. Since the 2010s, improved access to genetic testing and the operation of multidisciplinary craniofacial clinics at major medical institutions have greatly improved diagnostic accuracy and access to treatment. Systematic epidemiological data are being built through the Korean rare disease registry system.

5. Pathophysiology

The pathophysiology of Crouzon disease is understood to center on constitutive activation of the FGF signaling pathway by FGFR2 gain-of-function variants. After FGF ligand binding, FGFR2 undergoes dimerization and autophosphorylation, which activates downstream signaling pathways such as RAS-ERK, PI3K-AKT, PLC-γ and STAT. In normal suture development, FGF signaling maintains an appropriate balance of proliferation and differentiation of suture mesenchymal stem cells and preserves suture patency.

Cellular consequences of constitutive FGFR2 activation: abnormal disulfide bonds caused by cysteine residue substitutions dimerize FGFR2 independently of ligand and keep the tyrosine kinase domain continuously active. As a result, osteoblast differentiation from suture mesenchymal stem cells (osteoprogenitors) is prematurely promoted, and the pool of undifferentiated mesenchymal cells needed to maintain suture patency is depleted. Increased ERK1/2 phosphorylation, upregulation of RUNX2 (a transcription factor for bone differentiation) and shortening of the cell cycle contribute to accelerated ossification. At the same time, FGF signaling hyperactivation increases apoptosis of suture mesenchymal cells, accelerating the loss of normal suture tissue.

Mechanism of midface retrusion: growth failure of the skull base due to premature fusion of cranial sutures is the core mechanism of midface hypoplasia. Premature suture fusion limiting development of the sphenoid, ethmoid and maxilla causes upper airway narrowing and reduced orbital volume. As a result, exophthalmos/proptosis occurs, with the eyes protruding out of the orbits, and airway narrowing of the nasopharynx and oropharynx leads to sleep apnea. Mechanism of raised intracranial pressure: when premature multisutural fusion prevents cranial volume from keeping pace with brain growth, intracranial pressure rises. In Crouzon disease, raised intracranial pressure occurs in about 35–60%, and chronic hypercapnia due to sleep apnea further raises intracranial pressure. Accompanying Chiari I malformation (cerebellar tonsillar descent, reported in about 70%) obstructs cerebrospinal fluid flow and contributes to raised intracranial pressure.

6. Symptoms

The clinical symptoms of Crouzon disease consist of cranial and midface deformities, raised intracranial pressure, ocular and visual abnormalities, airway problems and hearing abnormalities. Symptom severity ranges from mild to severe depending on the number and timing of fused sutures, the location of the FGFR2 variant and interindividual phenotypic variability.

Cranial deformity: premature multisutural fusion of the coronal, sagittal, lambdoid and other sutures produces various abnormal skull shapes. Bilateral coronal suture fusion is the most common, so brachycephaly or turricephaly is characteristic. The forehead is flat, and a turricephalic deformity with vertical enlargement of the head may develop. The occiput may also be flattened. Midface retrusion causes the central face (nose, maxilla, cheekbones) to be set back and the mandible to appear relatively protruded, a characteristic facial form.

Proptosis and visual symptoms: exophthalmos due to reduced orbital volume is one of the most distinctive features of Crouzon disease. Severe proptosis prevents complete eyelid closure, causing exposure keratopathy, corneal ulcers and, in severe cases, globe luxation. Persistent raised intracranial pressure leads to papilledema, optic atrophy, reduced visual acuity and visual field defects. Strabismus and refractive errors are also common. Symptoms of raised intracranial pressure: infants show irritability, sleep disturbance, feeding refusal and developmental delay, while older children show headache (especially worse in the morning), nausea and vomiting, and abducens nerve palsy (esotropia).

Airway and sleep symptoms: nasopharyngeal narrowing due to midface retrusion and choanal stenosis/atresia cause nasal–oral breathing disturbance, obstructive sleep apnea (OSA) and snoring. Severe airway narrowing can cause acute respiratory failure in the neonatal period. Hearing abnormalities: external auditory canal stenosis, otitis media with effusion due to Eustachian tube dysfunction, and conductive hearing loss due to ossicular malformations are reported in about 50–60%. Some also have sensorineural hearing loss. Other: there is no syndactyly of the fingers or toes or widespread limb abnormality (a key distinguishing point from Apert syndrome), but cervical spine abnormalities (C5-C6 fusion) are rarely reported.

7. Signs

The physical signs of Crouzon disease are evident from the neonatal period and are evaluated by systematic examination of skull shape and the ophthalmologic, airway and neurologic systems.

Skull shape signs: increased cephalic index (CI) (brachycephaly, CI > 85) or turricephalic deformity, flattening of the forehead and flattening of the occiput are observed. Palpation of the cranial sutures reveals a ridge at fused suture sites or loss of the suture. Early closure or bulging of the anterior fontanelle suggests raised intracranial pressure. On skull X-ray or CT, digital markings (copper beaten skull) are a radiologic sign of raised intracranial pressure. Midface and orbital signs: retrusion of the maxilla and zygoma makes midface retrusion evident, with the upper lip and nasal base set back. Proptosis (Hertel exophthalmometer measurement ≥ 18mm or asymmetry between the eyes of 2mm or more), upward–outward slanting of the palpebral fissures (antimongoloid slant) and incomplete eyelid closure are prominent.

Ophthalmologic signs: on fundoscopy, papilledema is an objective indicator of raised intracranial pressure. With progression, optic atrophy and optic disc pallor appear. Strabismus (exotropia or esotropia) and a V-pattern strabismus are observed, and visual acuity and refraction testing commonly show refractive errors (especially myopia or astigmatism). Corneal dryness and corneal opacity may occur due to exposure keratopathy. Airway and hearing signs: nasal endoscopy confirms choanal stenosis or atresia. Otoscope examination shows external auditory canal stenosis and middle ear effusion. Audiometry shows a conductive hearing loss pattern. On polysomnography, an increased apnea–hypopnea index (AHI) confirms obstructive sleep apnea. Neurologic signs: with raised intracranial pressure, esotropia due to abducens nerve palsy appears, and in advanced cases papilledema and optic atrophy. Brain MRI may reveal Chiari I malformation (cerebellar tonsillar descent of 5mm or more), hydrocephalus and brain malformations. In acanthosis nigricans (FGFR3 variant type), hyperpigmented, hyperkeratotic skin changes of the neck, axillae and groin are observed on examination.

8. Screening

There is no large-scale newborn screening program for Crouzon disease, but prenatal ultrasound and neonatal physical examination are the practical screening tools. In high-risk groups with a family history, prenatal genetic analysis is applied.

Prenatal ultrasound: if routine second- or third-trimester ultrasound suggests abnormal skull shape (brachycephaly, flattened forehead, abnormal cephalic index), orbital protrusion or midface retrusion, craniosynostosis syndromes including Crouzon disease should be considered in the differential. Brachycephalic deformity due to bilateral coronal suture fusion can be detected by ultrasound in the third trimester (28–32 weeks). If prenatal ultrasound findings are unclear, fetal MRI is added to evaluate accompanying brain structural abnormalities.

Prenatal genetic testing: when there is a family member with Crouzon disease or a confirmed FGFR2 variant carrier, targeted analysis for that variant is performed on fetal DNA obtained by chorionic villus sampling (CVS) at 11–14 weeks of gestation or amniocentesis at 15–20 weeks. In families at high risk of de novo mutation (advanced paternal age), comprehensive FGFR panel testing may be more effective than targeted gene analysis. Neonatal physical examination: immediately after birth, head shape, forehead shape, orbital and ocular findings and nasal airway patency are evaluated. If proptosis, midface retrusion or abnormal head shape is identified, skull CT, genetic testing and ophthalmology and otolaryngology consultation are started immediately. Family screening: because family members (parents, siblings) of patients with Crouzon disease may include undiagnosed carriers with mild phenotypes, clinical evaluation (head shape, proptosis, ophthalmologic findings) and, if needed, genetic testing are performed for the families of affected patients.

9. Diagnosis

Diagnosis of Crouzon disease is established through an integrated approach of clinical evaluation, imaging and genetic analysis. The goals of diagnosis are ① to confirm craniosynostosis and craniofacial dysmorphism, ② to identify the causative gene variant, and ③ to evaluate accompanying complications such as raised intracranial pressure, optic nerve abnormalities and airway problems.

Skull CT with 3D reconstruction: the standard imaging test for diagnosing craniosynostosis. 3D reconstruction of thin-slice (≤ 1mm) skull CT provides three-dimensional evaluation of the extent and location of fused sutures, skull base structure, orbital volume and midface anatomy. Suture obliteration, suture sclerosis, skull base shortening and reduced orbital volume are the CT features of Crouzon disease. 3D CT images are essential for surgical planning, pre- and postoperative comparison and assessment of recurrence.

Brain MRI: evaluates Chiari I malformation (cerebellar tonsillar descent of 5mm or more, present in about 70% of Crouzon disease), hydrocephalus, aqueductal stenosis and abnormalities of brain development. Optic nerve MRI (T2, FLAIR) confirms optic atrophy or compression. Brain MRI is essential at initial evaluation and before surgery and is repeated whenever raised intracranial pressure is suspected. Ophthalmologic examination: fundoscopy (papilledema, optic atrophy), visual acuity, refraction, strabismus evaluation, proptosis measurement, OCT (optic nerve thickness). Papilledema or optic atrophy suggests the need for immediate intracranial pressure decompression. Molecular genetic testing: the FGFR2 gene (focused analysis of exons IIIa and IIIc followed by whole-gene analysis) is tested first and, if negative, a craniosynostosis panel including FGFR1 and FGFR3 or WES is performed. If acanthosis nigricans is present, targeted analysis for FGFR3 p.A391E is added. Airway evaluation: choanal stenosis is evaluated by nasal endoscopy, and the severity of obstructive sleep apnea is quantified by polysomnography (PSG). Hearing tests: pure-tone audiometry, otoacoustic emissions (OAE) and auditory brainstem response (ABR) assess conductive and sensorineural hearing loss. The results are used as the basis for deciding on insertion of a pressure equalization tube.

10. Treatment

Treatment of Crouzon disease requires a multidisciplinary approach that includes cranial reshaping, midface correction, airway management, ophthalmologic treatment, hearing rehabilitation and developmental support. Treatment proceeds in stages from the neonatal period to adulthood, combining surgical and nonsurgical treatment optimized for each stage.

Cranial vault remodeling: cranial vault remodeling is performed at 6–12 months of age with the goals of preventing raised intracranial pressure and correcting skull shape. In bilateral coronal suture fusion, Frontal Orbital Advancement (FOA) advances the frontal region and supraorbital rim to expand cranial volume and correct forehead shape. In multisutural fusion with severely raised intracranial pressure, posterior cranial vault remodeling or cranial vault expansion is performed first. Gradual cranial expansion using endoscopic assistance or distraction osteogenesis is used as a minimally invasive alternative.

Midface advancement: to correct midface retrusion, proptosis and airway narrowing, LeFort III osteotomy or monobloc osteotomy is generally performed after age 6–10 years (after a certain amount of bone growth has occurred). Distraction osteogenesis advances the bone gradually over several weeks using an external or internal distraction device, which can reduce overcorrection and relapse. In infants with severe airway problems, early midface advancement may be considered, in which case internal distraction is preferred. Final corrective surgery in adulthood (combined LeFort I, II and III osteotomies, orthognathic surgery) is performed after facial growth is complete.

Airway management: CPAP (continuous positive airway pressure) therapy is effective for mild to moderate sleep apnea. Tracheostomy may be needed for severe upper airway narrowing or for airway protection before midface advancement surgery. Tonsillectomy and adenoidectomy help reduce sleep apnea in some patients. Ophthalmologic treatment: exposure keratopathy is managed with artificial tears, eye ointment, moisture chamber glasses and the like, and in severe cases tarsorrhaphy is needed. Strabismus is treated with strabismus surgery. If papilledema is identified, intracranial pressure decompression surgery (cranial vault remodeling or ventriculoperitoneal shunt) takes priority. Hearing rehabilitation: middle ear ventilation tubes are inserted for otitis media with effusion, and hearing aids or bone-anchored hearing aids (BAHA) are used for moderate or greater hearing loss. Developmental support: speech therapy, neuropsychological evaluation, learning support and psychological counseling are included in comprehensive developmental support.

11. Prognosis

The prognosis of Crouzon disease varies greatly depending on early detection and management of raised intracranial pressure, the timing and quality of surgery, whether vision is preserved and the adequacy of airway management.

Intelligence and cognitive development: most patients with Crouzon disease whose intracranial pressure is adequately managed have intelligence within the normal range. However, when intracranial pressure has been elevated for a long time, especially with persistent papilledema, the risk of cognitive decline, delayed language development and learning disabilities increases. Early surgery (before or immediately after the onset of raised intracranial pressure) is the key determinant of neurodevelopmental outcome. Some studies have reported that patients with Crouzon disease can generally complete a normal education and hold independent jobs.

Visual prognosis: if papilledema persists or optic atrophy develops, irreversible vision loss may remain. Regular ophthalmologic follow-up and timely decompression of intracranial pressure are decisive for preserving vision. Corneal damage from exposure keratopathy also affects vision, so ongoing care to protect the cornea is needed. Airway and sleep prognosis: sleep apnea often improves significantly after midface advancement, but some patients need continued CPAP therapy or additional surgery. If airway problems are not resolved early, chronic hypoxemia and hypercapnia worsen raised intracranial pressure and degrade the overall prognosis. Repeated surgery: patients with Crouzon disease commonly undergo multiple operations during growth, including cranial vault remodeling, midface advancement, ophthalmologic surgery and otolaryngologic procedures. At each surgical stage, careful preparation for anesthetic risk, airway management and bleeding is needed. Psychosocial prognosis: social stigma due to facial dysmorphism, difficulties in peer relationships and low self-esteem can lead to psychological problems. Early psychological intervention, peer support groups and school education support are important for social participation and improved quality of life.

12. Prevention

Complete primary prevention of Crouzon disease is currently impossible. However, prevention of complications through genetic counseling, prenatal diagnosis and early detection and treatment (secondary and tertiary prevention) is clinically important.

Genetic counseling and prenatal diagnosis: the spouse of a patient with Crouzon disease should receive sufficient information from a genetic counseling specialist about the risk (50%) of occurrence in their children. In families carrying a confirmed FGFR2 variant, prenatal genetic analysis by CVS or amniocentesis during pregnancy determines whether the fetus is affected. Selectively transferring affected embryos through preimplantation genetic testing (PGT) is also possible. For patients whose disease arose from a de novo mutation, prenatal diagnosis is recommended in subsequent pregnancies as well because of the possibility of gonadal mosaicism.

Prevention of complications (secondary prevention): early diagnosis and regular follow-up enable early detection and preventive treatment of raised intracranial pressure, vision loss and sleep apnea. Regular ophthalmologic examinations (at least every 6 months to 1 year) detect papilledema early and prevent irreversible optic nerve damage. Early diagnosis of sleep apnea by polysomnography and CPAP therapy prevent worsening of intracranial pressure. Regular hearing tests and appropriate hearing rehabilitation prevent delays in language and cognitive development. Prevention of raised intracranial pressure (tertiary prevention): staged surgical treatment including cranial vault remodeling is the key means of preventing neurologic damage from chronically raised intracranial pressure. Even after surgery, long-term follow-up monitors for re-elevation of intracranial pressure. Thorough education of patients and families (warning symptoms, the importance of regular follow-up, responding to emergencies) is the best tertiary prevention.

13. References

  1. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet. 1994;8(1):98-103. DOI: 10.1038/ng0994-98. PMID: 7987400.

  2. Jabs EW, Li X, Scott AF, et al. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet. 1994;8(3):275-279. DOI: 10.1038/ng1194-275. PMID: 7874170.

  3. Cohen MM Jr, Kreiborg S. The central nervous system in the Apert syndrome. Am J Med Genet. 1990;35(1):36-45. DOI: 10.1002/ajmg.1320350108. PMID: 2301456.

  4. Renier D, Arnaud E, Cinalli G, Sebag G, Zerah M, Marchac D. Prognosis for mental function in Apert's syndrome. J Neurosurg. 1996;85(1):66-72. DOI: 10.3171/jns.1996.85.1.0066. PMID: 8683274.

  5. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995;11(4):462-464. DOI: 10.1038/ng1295-462. PMID: 7493034.

  6. Cinalli G, Sainte-Rose C, Kollar EM, et al. Hydrocephalus and craniosynostosis. J Neurosurg. 1998;88(2):209-214. DOI: 10.3171/jns.1998.88.2.0209. PMID: 9452224.

  7. Fearon JA, Whitaker LA. Complications with facial advancement: a comparison between the Le Fort III and monobloc advancements. Plast Reconstr Surg. 1993;91(6):990-995. DOI: 10.1097/00006534-199305000-00002. PMID: 8479982.

  8. Kreiborg S, Cohen MM Jr. The oral manifestations of Apert syndrome. J Craniofac Genet Dev Biol. 1992;12(1):41-48. PMID: 1592017.

  9. Arnaud E, Marchac D, Renier D. Reduction of increased intracranial pressure after fi-ber-optic monitoring-guided craniosynostosis surgery. Pediatr Neurosurg. 1995;22(1):24-29. DOI: 10.1159/000120877. PMID: 7710730.

  10. Wilkie AOM, Byren JC, Hurst JA, et al. Prevalence and complications of single-gene and chromosomal disorders in craniosynostosis. Pediatrics. 2010;126(2):e391-400. DOI: 10.1542/peds.2009-3491. PMID: 20643724.